A Case of Fatal Bleeding Following Emergency Surgery on an Ascending Aorta Intramural Hematoma in a Patient Taking Dabigatran

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 30, Issue 4, 2016, Pages 1027-1031

  Crapelli, Giulia Beatrice ^a   Bianchi, Paolo ^a   Isgrò, Giuseppe ^a   Biondi, Andrea ^b   de Vincentiis, Carlo ^b   Ranucci, Marco ^a  

^a Departments of Cardiothoracic Vascular Anesthesia and Intensive Care   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

bleeding; coagulation point of care tests; dabigatran; emergency surgery; ROTEM

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DABIGATRAN ETEXILATE; FIBRINOGEN; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; HEPARIN; HEPARIN LYASE; INOTROPIC AGENT; PROTAMINE SULFATE; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; ANTITHROMBIN; DABIGATRAN;

AGED; ANTICOAGULANT THERAPY; AORTA CLAMPING; ARTICLE; ARTIFICIAL VENTILATION; ASCENDING AORTA SURGERY; BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BRACHIOCEPHALIC TRUNK; BRAIN PERFUSION; CARDIOPULMONARY BYPASS; CASE REPORT; CHEST TUBE; COMPUTER ASSISTED TOMOGRAPHY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG FATALITY; EMERGENCY SURGERY; EMERGENCY WARD; ERYTHROCYTE CONCENTRATE; FAINTNESS; FEMALE; GLOMERULUS FILTRATION RATE; HEART ARREST; HEART TAMPONADE; HEMATOLOGIC DISEASE; HEMATOMA; HEMOSTASIS; HUMAN; HYPERFIBRINOLYSIS; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; MAXIMUM CLOT FIRMNESS; PAROXYSMAL ATRIAL FIBRILLATION; PARTIAL THROMBOPLASTIN TIME; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REACTION TIME; THORAX PAIN; THROMBOCYTE COUNT; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; TREATMENT DURATION; ULTRAFILTRATION; VERY ELDERLY; VISCOELASTICITY; AORTA; AORTIC DISEASES; EMERGENCY TREATMENT; FATALITY; PATHOPHYSIOLOGY; POSTOPERATIVE HEMORRHAGE; PROCEDURES;

AGED, 80 AND OVER; ANTITHROMBINS; AORTA; AORTIC DISEASES; DABIGATRAN; EMERGENCY TREATMENT; FATAL OUTCOME; FEMALE; HEMATOMA; HUMANS; POSTOPERATIVE HEMORRHAGE;

EID: 84969983849     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2015.10.017     Document Type: Article

References (19)

1. 1 Erbel, R., Aboyans, V., Boileau, C., et al. ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 35 (2014), 2873–2926.
2. 2 European Medicines Agency – Pradaxa: EPAR product information. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed October 15, 2015.
3. 3 European Medicines Agency – Praxbind: CHMP summary of positive opinion for Praxabind. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003986/WC500194147.pdf. Accessed October 15, 2015.
4. 4 Heidbuchel, H., Verhamme, P., Alings, M., et al. Practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15 (2013), 625–651.
5. 5 Van Ryn, J., Goss, A., Hauel, N., et al. The discovery of dabigatran etexilate. Front Pharmacol, 4, 2013, 12.
6. 6 Khadzhynov, D., Wagner, F., Formella, S., et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 109 (2013), 596–605.
7. 7 Singh, T., Maw, T.T., Henry, B.L., et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: A single center experience. Clin J Am Soc Nephrol 8 (2013), 1533–1539.
8. 8 Muddana N, Thuyanh C, Nayer A, et al: Use of extracorporeal techniques in the removal of dabigatran. Am J Ther 2014 [Epub ahead of print].
9. 9 Chai-Adisaksopha, C., Hillis, C., Lim, W., et al. Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review. J Thromb Haemost 13 (2015), 1790–1798.
10. 10 Stein, P., Bosshart, M., Brand, B., et al. Dabigatran anticoagulation and Stanford type A aortic dissection: Lethal coincidence: Case report with literature review. Acta Anaesthesiol Scand 58 (2014), 630–637.
11. 11 Ashikhmina, E., Tomasello, N., Connors, J.M., et al. Type A aortic dissection in a patient on dabigatran: Hemostasis post circulatory arrest. Ann Thorac Surg 98 (2014), 2215–2216.
12. 12 Siegal, D.M., Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 39 (2015), 395–402.
13. 13 Faraoni, D., Levy, J.H., Albaladejo, P.F., et al. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care, 19, 2015, 203.
14. 14 Franchini, M., Bonfanti, C., Mannucci, P.M., Management of bleeding associated with new oral anticoagulants. Semin Thromb Hemost 41 (2015), 788–801.
15. 15 Williamson, L.D., Maxwell, E., Silvers, AJ, et al. Dabigatran anticoagulation and Stanford type A aortic dissection: Not always a lethal coincidence?. Acta Anaesthesiol Scand 8 (2014), 1160–1161.
16. 16 Mastrobuoni, S., Robblee, J.A., Boodhwani, M., Spontaneous ascending aortic intramural haematoma in a patient on dabigatran. Interact Cardiovasc Thorac Surg 15 (2012), 299–300.
17. 17 Glund, S., Stangier, J., Schmohl, M., et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386 (2015), 680–690.
18. 18 Glund, S., Moschetti, V., Norris, S., et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 113 (2015), 943–951.
19. 19 Pollack, C.V. Jr, Reilly, P.A., Eikelboom, J., et al. Idarucizumab for dabigatran reversal. N Engl J Med 373 (2015), 511–520.